Colorectal Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR109 MIFTS: 54	Colorectal Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of Large Intestine ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050861

UMLS ⁷³ C1319315

Sources

Summaries for Colorectal Adenocarcinoma

Disease Ontology : ¹² A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to adenocarcinoma and colorectal adenoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lymph node, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	31.4	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
2	colorectal adenoma	31.3	CTNNB1 HRAS KRAS MLH1 MSH2 TP53
3	gastrointestinal stromal tumor	30.5	BRAF EGFR KRAS TP53
4	renal cell carcinoma, nonpapillary	30.1	CDH1 EGFR KRT20 KRT7
5	chordoma	30.0	CDH1 EGFR KRT7
6	villous adenoma	29.9	BRAF CDX2 KRAS KRT20
7	adenoma	29.9	BRAF CTNNB1 KRAS MLH1 MSH2 TP53
8	mucinous bronchioloalveolar adenocarcinoma	29.8	CDX2 KRT20 KRT7
9	squamous cell carcinoma	29.6	BRAF CDH1 CTNNB1 EGFR HRAS TP53
10	bladder adenocarcinoma	29.5	CDX2 CTNNB1 HRAS KRT20 KRT7
11	familial adenomatous polyposis	29.5	CDH1 CTNNB1 KRAS MLH1 MSH2 TP53
12	ulcerative colitis	29.4	CTNNB1 MLH1 MSH2 MUC2
13	lynch syndrome	29.3	BRAF CTNNB1 EGFR KRAS MLH1 MSH2
14	mucinous adenocarcinoma	29.3	CDX2 EGFR KRAS KRT20 KRT7 MLH1
15	hepatocellular carcinoma	29.1	CDH1 CEACAM5 CTNNB1 EGFR HRAS KRAS
16	esophageal cancer	29.0	CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
17	lung cancer	28.9	BRAF CDH1 CEACAM5 EGFR HRAS KRAS
18	lung cancer susceptibility 3	28.7	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
19	cholangiocarcinoma	28.7	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
20	colorectal cancer	28.5	AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
21	gastric adenocarcinoma	28.3	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
22	intestinal disease	28.3	CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
23	nevus of ota	10.4	BRAF TP53
24	rare adenocarcinoma of the breast	10.4	KRAS TP53
25	vulvar intraepithelial neoplasia	10.4	KRT7 TP53
26	seminal vesicle adenocarcinoma	10.4	KRT20 KRT7
27	transverse colon cancer	10.4	KRT20 KRT7
28	colloid adenoma	10.4	KRT20 TP53
29	papillary transitional carcinoma	10.4	KRT20 KRT7
30	cystic basal cell carcinoma	10.4	KRT20 KRT7
31	malignant syringoma	10.3	KRT20 KRT7
32	krukenberg carcinoma	10.3	KRT20 KRT7
33	small cell carcinoma of the bladder	10.3	KRT20 KRT7
34	ovary neuroendocrine neoplasm	10.3	CDX2 KRT7
35	vaginal benign neoplasm	10.3	CDX2 KRT20
36	vaginal adenoma	10.3	CDX2 KRT20
37	vaginal tubulovillous adenoma	10.3	CDX2 KRT20
38	cerebral convexity meningioma	10.3	CDH1 TP53
39	renal pelvis adenocarcinoma	10.3	CDH1 KRT7
40	brain ependymoma	10.3	EGFR TP53
41	benign breast adenomyoepithelioma	10.3	EGFR KRT7
42	oncocytic breast carcinoma	10.3	EGFR KRT7
43	intracranial chondrosarcoma	10.3	CEACAM5 TP53
44	cutaneous mucoepidermoid carcinoma	10.3	CEACAM5 KRT7
45	anal gland adenocarcinoma	10.3	CEACAM5 KRT7
46	anal paget's disease	10.3	CDX2 CEACAM5
47	ovarian clear cell carcinoma	10.3	KRAS KRT7 TP53
48	esophageal adenosquamous carcinoma	10.3	CDH1 CEACAM5
49	sweat gland cancer	10.3	KRT20 KRT7 TP53
50	adult hepatocellular carcinoma	10.3	CTNNB1 TP53

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:

Sources

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 16)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.92	AURKA EGFR HRAS KRAS PIM2 BRAF
2	Decreased viability	GR00106-A-0	10.92	KRAS
3	Decreased viability	GR00173-A	10.92	CDK8
4	Decreased viability	GR00221-A-1	10.92	AURKA CDH1 CDK8 EGFR HRAS KRAS
5	Decreased viability	GR00221-A-2	10.92	AURKA CDK8 HRAS KRAS
6	Decreased viability	GR00221-A-3	10.92	HRAS
7	Decreased viability	GR00221-A-4	10.92	AURKA CDK8 EGFR BRAF
8	Decreased viability	GR00231-A	10.92	AURKA
9	Decreased viability	GR00301-A	10.92	CDH1 CDK8 KRAS PIM2 BRAF MSH2
10	Decreased viability	GR00381-A-1	10.92	KRAS BRAF
11	Decreased viability	GR00402-S-2	10.92	AURKA CDH1 CDK8 EGFR HRAS KRAS
12	Decreased cell migration	GR00055-A-1	9.97	AURKA BRAF CDK8 CTNNB1 EGFR HRAS
13	Decreased viability in esophageal squamous lineage	GR00235-A	9.9	AURKA BRAF CDH1 CDK8 CTNNB1 FABP6
14	Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection	GR00234-A-2	9.5	BRAF CDK8 EGFR
15	Increased cell migration	GR00055-A-3	9.43	AURKA BRAF CTNNB1 EGFR HRAS KRAS
16	Increased cell viability after pRB stimulation	GR00230-A-1	8.92	AURKA CDK8 EGFR PIM2

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

⁴⁶ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.27	AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
2	digestive/alimentary	MP:0005381	10.22	BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
3	homeostasis/metabolism	MP:0005376	10.22	BRAF CDH1 CDX2 CTNNB1 EGFR FABP6
4	mortality/aging	MP:0010768	10.17	AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
5	endocrine/exocrine gland	MP:0005379	10.13	BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
6	embryo	MP:0005380	10.11	AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
7	neoplasm	MP:0002006	10.03	AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
8	integument	MP:0010771	10.02	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
9	no phenotypic analysis	MP:0003012	9.7	AURKA CDH1 CTNNB1 EGFR HRAS KRAS
10	pigmentation	MP:0001186	9.35	BRAF CTNNB1 EGFR KRAS TP53
11	renal/urinary system	MP:0005367	9.17	BRAF CTNNB1 EGFR HRAS KRAS KRT7

Sources

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved

Phase 4

7439-89-6

23925

Ferric Compounds

Phase 4

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Hepcidins

Phase 4

Iron Supplement

Phase 4

Oxaliplatin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

61825-94-3

43805 6857599 5310940 9887054

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Phase 1

68538-85-2

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

51-21-8

3385

leucovorin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

6006 143

Irinotecan

Approved, Investigational

Phase 2, Phase 3,Phase 1

100286-90-6, 97682-44-5

60838

Atezolizumab

Approved, Investigational

Phase 3,Phase 2

1380723-44-3

Nicotine

Approved

Phase 3

54-11-5

942 89594

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

59-30-3

6037

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Protective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Calcium, Dietary

Phase 3,Phase 2

Antidotes

Phase 3,Phase 2,Phase 1,Not Applicable

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Liver Extracts

Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 3,Phase 2

Micronutrients

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B9

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamins

Phase 3,Phase 2,Phase 1,Not Applicable

Trace Elements

Phase 3,Phase 2,Phase 1,Not Applicable

Folate

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B Complex

Phase 3,Phase 2,Phase 1,Not Applicable

Bone Density Conservation Agents

Phase 3,Phase 2

Immunoglobulin G

Phase 3,Phase 2

Endothelial Growth Factors

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2,Phase 1

Tetrahydrofolates

Phase 3

Formyltetrahydrofolates

Phase 3

Mitomycins

Phase 2, Phase 3

s 1 (combination)

Phase 3

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2,Phase 1

53123-88-9

46835353 6436030 5284616

Everolimus

Approved

Phase 2,Phase 1

159351-69-6

6442177

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Interventional clinical trials:

(show top 50) (show all 133)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Iron: Measuring Response in Anemic Surgical Patients	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
2	IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia	Completed	NCT01701310	Phase 4	Ferric carboxymaltose;Ferrous Sulphate
3	A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)	Completed	NCT02788279	Phase 3	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4	Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases	Completed	NCT00265356	Phase 3
5	A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	Completed	NCT00623805	Phase 3	Bevacizumab;Capecitabine;Oxaliplatin
6	Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM	Recruiting	NCT03125161	Phase 3	HAI;chemotherapy ± target therapy
7	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer	Recruiting	NCT02997228	Phase 3	Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab	Recruiting	NCT03300609	Phase 3	Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
9	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases	Recruiting	NCT02758951	Phase 2, Phase 3
10	Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）	Active, not recruiting	NCT02390947	Phase 3	Famitinib;Placebo
11	Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma	Not yet recruiting	NCT03708536	Phase 3	S-1;Bevacizumab;Capecitabine
12	TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)	Not yet recruiting	NCT03783559	Phase 3	TACE;chemotherapy±target therapy
13	Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma	Unknown status	NCT01552967	Phase 2	Capecitabine
14	Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .	Unknown status	NCT02788006	Phase 2	Regorafenib 160 mg
15	Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.	Unknown status	NCT01067053	Phase 2	bevacizumab, capecitabine, oxaliplatin
16	Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma	Unknown status	NCT00075556	Phase 2	capecitabine
17	Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00544011	Phase 2	capecitabine;fluorouracil;irinotecan hydrochloride
18	Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer	Unknown status	NCT00104689	Phase 2	capecitabine;oxaliplatin
19	Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00027833	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20	Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma	Completed	NCT00034190	Phase 2	S-8184 Paclitaxel Injectable Emulsion
21	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	Completed	NCT01900717	Phase 2	LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
22	Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma	Completed	NCT00168155	Phase 2	perioperative chemotherapy
23	Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.	Completed	NCT02181465	Phase 2
24	Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma	Completed	NCT00574171	Phase 2	lapatinib;Capecitabine
25	Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma	Completed	NCT01479465	Phase 2	Simtuzumab;FOLFIRI;Placebo to match simtuzumab
26	DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma	Completed	NCT00080834	Phase 2	DJ-927
27	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy	Completed	NCT00419159	Phase 2	Everolimus (RAD001)
28	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	Completed	NCT00597506	Phase 2	Bevacizumab;Everolimus
29	Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Completed	NCT00165217	Phase 2	Capecitabine;Thalidomide
30	Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas	Completed	NCT01730586	Phase 2	Abraxane
31	Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib	Completed	NCT00582660	Phase 2	Celecoxib;Placebo
32	Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer	Completed	NCT00003220	Phase 2	bryostatin 1
33	Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer	Completed	NCT00025350	Phase 2	gefitinib
34	Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone	Completed	NCT00890305	Phase 2	CT-011;FOLFOX
35	Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver	Completed	NCT00149396	Phase 1, Phase 2	NV1020
36	1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer	Completed	NCT01417494	Phase 2	Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
37	Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer	Completed	NCT00123851	Phase 2	Tarceva (OSI-774);Capecitabine;Oxaliplatin
38	Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy	Completed	NCT01225744	Phase 2	Cetuximab;Irinotecan;Oxaliplatin;UFT
39	Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed	Completed	NCT00259844	Phase 2
40	Azacitidine and CAPOX in Metastatic Colorectal Cancer	Completed	NCT01193517	Phase 1, Phase 2	Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
41	Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma	Recruiting	NCT01844076	Phase 1, Phase 2	Phase I (Quinacrine);Capecitabine
42	Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma	Recruiting	NCT03559543	Phase 2
43	FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation	Recruiting	NCT03584711	Phase 2
44	Chemotherapy and/or Metastasectomy in Treating Participants With Metastatic Colorectal Adenocarcinoma With Lung Metastases	Recruiting	NCT03599752	Phase 2	Chemotherapy
45	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	Recruiting	NCT02185443	Phase 2
46	Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer	Recruiting	NCT03642067	Phase 2	Nivolumab;Relatlimab
47	Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver	Recruiting	NCT03069950	Phase 2	Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
48	Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA)	Recruiting	NCT02738606	Phase 2	Chemotherapy
49	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Recruiting	NCT03442569	Phase 2	Panitumumab;Nivolumab;Ipilimumab
50	Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer	Recruiting	NCT01053013	Phase 2

Search NIH Clinical Center for Colorectal Adenocarcinoma

Sources

Genetic Tests for Colorectal Adenocarcinoma

Sources

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

⁴¹

Liver, Colon, Lymph Node, Lung, Testes, Endothelial, Thyroid

Sources

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 951)

#	Title	Authors	Year
1	Histology of colorectal adenocarcinoma with double somatic mismatch repair mutations is indistinguishable from those caused by lynch syndrome. ( 29723603 )	Hemminger J.A....Frankel W.L.	2018
2	SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )	Shen P....Zhou D.	2018
3	MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )	RAosAonen K....Stenman J.	2018
4	Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )	Miyamoto R....Yamamoto M.	2018
5	Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )	Nemanqani D.M....Al-Sufyani W.M.	2018
6	In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )	Mobini G.R....Heidari M.	2018
7	Cellular mechanism of resistance of human colorectal adenocarcinoma cells against apoptosis-induction by Russell's Viper venom l-amino acid oxidase (Rusvinoxidase). ( 29702182 )	Mukherjee A.K....Mackessy S.P.	2018
8	Hepatobiliary and Pancreatic: Hepatic nodules in a patient with familial adenomatous polyposis and colorectal adenocarcinoma. ( 29284077 )	CrimA- F....Pomerri F.	2018
9	Localized lymphoid hyperplasia of the spleen mimicking metastatic colorectal adenocarcinoma. ( 29952067 )	Huynh F....Smith M.	2018
10	MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. ( 29641976 )	Zhang M....Du X.	2018
11	Predictors for local recurrence and distant metastasis of mucinous colorectal adenocarcinoma. ( 29361368 )	Emile S.H....Khafagy W.	2018
12	Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues. ( 29285188 )	Tokuhara Y....Hirakawa E.	2018
13	Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma. ( 29683067 )	Cao L.L....Wang H.	2018
14	Expression of GAEC1 mRNA and protein and its association with clinical and pathological parameters of patients with colorectal adenocarcinoma. ( 29337242 )	Wahab R....Lam A.K.	2018
15	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. ( 29955144 )	Papke D.J....Dong F.	2018
16	Investigating the association between African spontaneously fermented dairy products, faecal carriage of Streptococcus infantarius subsp. infantarius and colorectal adenocarcinoma in Kenya. ( 29079186 )	Kaindi D.W.M....Hattendorf J.	2018
17	Triple primary malignancies in a patient with colorectal adenocarcinoma: A case report. ( 29216528 )	Huang Q....Lian L.	2018
18	Decreased Expression of the Polarity Regulatory PAR Complex Predicts Poor Prognosis of the Patients with Colorectal Adenocarcinoma. ( 29220829 )	Yeo M.K....Kim K.H.	2018
19	High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. ( 29688883 )	Tsiakanikas P....Scorilas A.	2018
20	Colorectal Adenocarcinoma with an Alternative Serrated Pathway. ( 29805354 )	Eizuka M....Sugai T.	2018
21	Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. ( 29548809 )		2018
22	The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma. ( 29056035 )		2018
23	CT-based Radiomics Signature to Discriminate High-grade From Low-grade Colorectal Adenocarcinoma. ( 29503175 )		2018
24	Long Noncoding RNAs in Colorectal Adenocarcinoma; an in silico Analysis. ( 29948619 )		2018
25	Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: findings from three large US cohorts. ( 29873077 )		2018
26	p38 inhibitor inhibits the apoptosis of cowanin-treated human colorectal adenocarcinoma cells. ( 29620273 )		2018
27	Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. ( 29456855 )		2018
28	Ultrastructure of colorectal adenocarcinoma and peritumoral tissue in untreated patients. ( 29419351 )		2018
29	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. ( 30555542 )	Mai D...Lin D	2018
30	Down regulation of lncRNA MEG3 promotes colorectal adenocarcinoma cell proliferation and inhibits the apoptosis by up-regulating TGF-β1 and its downstream sphingosine kinase 1. ( 30556866 )	Dong X...Li SY	2018
31	Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. ( 30505575 )	Jensen CE...Loaiza-Bonilla A	2018
32	Investigation of the Anticancer Mechanism of Isoorientin Isolated from Eremurus Spectabilis Leaves via Cell Cycle Pathways in HT-29 Human Colorectal Adenocarcinoma Cells. ( 30515037 )	Gundogdu G...Karaoglan ES	2018
33	The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. ( 30466765 )	Cho J...Ha SY	2018
34	Isolated bone marrow metastases of colorectal adenocarcinoma. ( 30414232 )	O'Brien JM...Proud D	2018
35	Evaluation of Peritumoral Fibrosis in Metastatic Colorectal Adenocarcinoma to the Liver Using Digital Image Analysis. ( 30339201 )	Waters KM...Anders RA	2018
36	Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma. ( 30358195 )	Us?n PLS...Maluf FC	2018
37	Identification of LINC01234 and MIR210HG as novel prognostic signature for colorectal adenocarcinoma. ( 30362555 )	He Z...Zhang Z	2018
38	GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. ( 30321514 )	Yang Z...Xuan Y	2018
39	Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis. ( 30323980 )	Chen CH...Wu SY	2018
40	The Effect of LncRNA H19/miR-194-5p Axis on the Epithelial-Mesenchymal Transition of Colorectal Adenocarcinoma. ( 30278464 )	Li CF...Sun LB	2018
41	Computational analysis of mRNA expression profiles identifies a novel triple-biomarker model as prognostic predictor of stage II and III colorectal adenocarcinoma patients. ( 30214289 )	Cheng X...Hou D	2018
42	ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells. ( 30132516 )	Lei X...Li T	2018
43	Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors. ( 30134852 )	Lualdi M...Leo E	2018
44	Expression of leptin in colorectal adenocarcinoma showed significant different survival patterns associated with tumor size, lymphovascular invasion, distant metastasis, local recurrence, and relapse of disease in the western province of Saudi Arabia. ( 30142858 )	Al-Maghrabi JA...Khabaz MN	2018
45	Loss of BAP1 Expression Occurs Rarely to Never in Colorectal Adenocarcinoma. ( 28362705 )	Chui J...Gill AJ	2018
46	Additional lymphadenectomy might not improve survival of patients with resectable metastatic colorectal adenocarcinoma of T4 stage, proximal location, poor/undifferentiation, or N3/N4 stages: a large population-based study. ( 30026839 )	Zhou YY...Jin R	2018
47	SCF/c-KIT signaling promotes mucus secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma. ( 30034943 )	Li G...Zhou D	2018
48	Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma. ( 30061254 )	Lee YM...Kim KH	2018
49	[Polymorphisms of mTORC1 genes and risk of primary colorectal adenocarcinoma in Chinese populations]. ( 29996312 )		2018
50	Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( 28560404 )	Wang Y....Yin D.	2017

Sources

Genes for Colorectal Adenocarcinoma

Genes related to Colorectal Adenocarcinoma (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	FABP6	Fatty Acid Binding Protein 6	Protein Coding	29.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Functions (show sections)
2	AURKA	Aurora Kinase A	Protein Coding	27.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
3	FGFBP1	Fibroblast Growth Factor Binding Protein 1	Protein Coding	26.01	GeneCards inferred via : Publications Summaries (show sections)
4	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	25.69	GeneCards inferred via : Publications Variants (show sections)
5	TP53	Tumor Protein P53	Protein Coding	23.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	KRT7	Keratin 7	Protein Coding	23.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CDX2	Caudal Type Homeobox 2	Protein Coding	23.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	23.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MLH1	MutL Homolog 1	Protein Coding	22.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	22.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	KRT20	Keratin 20	Protein Coding	22.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	22.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	CDH1	Cadherin 1	Protein Coding	22.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	EGFR	Epidermal Growth Factor Receptor	Protein Coding	22.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	CTNNB1	Catenin Beta 1	Protein Coding	22.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	MSH2	MutS Homolog 2	Protein Coding	21.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	PIM2	Pim-2 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	15.61	GeneCards inferred via : Functions Expressions (show sections)
18	CDK8	Cyclin Dependent Kinase 8	Protein Coding	14.4	GeneCards inferred via : Publications Variants (show sections)
19	CEACAM5	Carcinoembryonic Antigen Related Cell Adhesion Molecule 5	Protein Coding	13.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	C2orf68	Chromosome 2 Open Reading Frame 68	Protein Coding	12.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	11.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	MSH6	MutS Homolog 6	Protein Coding	11.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Colorectal Adenocarcinoma

Sources

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Sources

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 66)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁶ Show member pathways Axon guidance ⁶⁶	13.52	BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2	fMLP Pathway ⁶⁴ Show member pathways Alpha-Adrenergic Signaling ⁶⁴ CCR3 Pathway in Eosinophils ⁶⁴ CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²² VEGF and S-1P Signaling ⁶⁴	12.98	BRAF CDH1 CDX2 CTNNB1 HRAS KRAS
3	MAPK signaling pathway ³⁷ ¹	12.78	BRAF EGFR HRAS KRAS TP53
4	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.77	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
5	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.75	BRAF CDH1 EGFR HRAS KRAS TP53
6	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.7	BRAF EGFR HRAS KRAS TP53
7	Ras signaling pathway ³⁷ Show member pathways Rap1 signaling pathway ³⁷	12.7	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
8	Pathways in cancer ³⁷	12.68	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
9	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.67	BRAF CDH1 CTNNB1 HRAS KRAS TP53
10	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.55	CTNNB1 EGFR HRAS KRAS MSH2 TP53
11	DNA Damage ⁴	12.54	AURKA CDK8 MLH1 MSH2 TP53
12	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.52	BRAF EGFR HRAS KRAS TP53
13	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.52	BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
14	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.5	BRAF EGFR HRAS KRAS TP53
15	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.46	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
16	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.45	CTNNB1 EGFR HRAS KRAS TP53
17	Human T-cell leukemia virus 1 infection ³⁷	12.43	CTNNB1 HRAS KRAS TP53
18	Arrhythmogenic right ventricular cardiomyopathy (ARVC) ³⁷ Show member pathways Arrhythmogenic Right Ventricular Cardiomyopathy ¹ Calpain Protease Regulates Cellular Mechanics ⁶⁴	12.43	CTNNB1 EGFR HRAS KRAS
19	Cushing syndrome ³⁷ Show member pathways Melanogenesis ³⁷	12.43	BRAF CTNNB1 EGFR HRAS KRAS
20	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.41	BRAF CTNNB1 HRAS KRAS
21	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ¹	12.38	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
22	Signaling by FGFR2 ⁶⁶ Show member pathways FGFR2 ligand binding and activation ⁶⁶ FGFR2b ligand binding and activation ⁶⁶ Signaling by FGFR ⁶⁶	12.29	BRAF FGFBP1 HRAS KRAS
23	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ Immune response Oncostatin M signaling via MAPK in human cells ²² MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.27	BRAF HRAS KRAS TP53
24	Proteoglycans in cancer ³⁷	12.24	BRAF CTNNB1 EGFR HRAS KRAS TP53
25	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.22	BRAF EGFR HRAS KRAS TP53
26	mTOR Pathway ⁷² Show member pathways Insulin Pathway ⁷² TGF-beta Pathway ⁷²	12.2	BRAF HRAS KRAS TP53
27	NGF Pathway ⁶⁴ Show member pathways TRKA Signaling ⁶⁴	12.17	BRAF HRAS KRAS TP53
28	AKT Signaling Pathway ⁶⁷	12.15	EGFR HRAS KRAS TP53
29	EGF/EGFR Signaling Pathway ¹	12.14	AURKA BRAF EGFR HRAS KRAS
30	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.12	BRAF EGFR HRAS KRAS
31	Direct p53 effectors ¹	12.09	EGFR MLH1 MSH2 TP53
32	UVA-Induced MAPK Signaling ⁶⁴ Show member pathways UVB-Induced MAPK Signaling ⁶⁴	12.08	EGFR HRAS KRAS TP53
33	G12-G13 in Cellular Signaling ⁶⁴	12.05	CDH1 CTNNB1 HRAS KRAS
34	Hepatitis C ³⁷	12.03	BRAF EGFR HRAS KRAS TP53
35	Thyroid hormone signaling pathway ³⁷	12.01	CTNNB1 HRAS KRAS TP53
36	DNA Damage Response (only ATM dependent) ¹	12	CTNNB1 HRAS KRAS TP53
37	Glioblastoma Multiforme ⁶⁴	11.93	BRAF CTNNB1 EGFR HRAS KRAS TP53
38	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants ⁶⁶ Show member pathways Constitutive Signaling by EGFRvIII ⁶⁶ Signaling by EGFR in Cancer ⁶⁶ Signaling by EGFRvIII in Cancer ⁶⁶ Signaling by Ligand-Responsive EGFR Variants in Cancer ⁶⁶	11.88	EGFR HRAS KRAS
39	Listeria monocytogenes entry into host cells ⁶⁶ Show member pathways E-cadherin signaling events ¹ EGFR downregulation ⁶⁶ InlA-mediated entry of Listeria monocytogenes into host cells ⁶⁶ InlB-mediated entry of Listeria monocytogenes into host cell ⁶⁶ Negative regulation of MET activity ⁶⁶	11.88	CDH1 CTNNB1 EGFR
40	Gap junction ³⁷	11.85	EGFR HRAS KRAS
41	VEGF Pathway (Tocris) ⁶¹ Show member pathways VEGF Pathway ⁷²	11.82	BRAF HRAS KRAS
42	Colorectal Cancer Metastasis ⁶⁴	11.78	BRAF CDH1 CTNNB1 EGFR KRAS MLH1
43	Platinum drug resistance ³⁷	11.76	MLH1 MSH2 TP53
44	Adherens junction ³⁷	11.75	CDH1 CTNNB1 EGFR
45	Bladder cancer ³⁷ ¹	11.71	BRAF CDH1 EGFR HRAS KRAS TP53
46	Mitophagy - animal ³⁷	11.7	HRAS KRAS TP53
47	Negative regulation of MAPK pathway ⁶⁶ Show member pathways RAF activation ⁶⁶	11.7	BRAF HRAS KRAS
48	Central carbon metabolism in cancer ³⁷	11.66	EGFR HRAS KRAS TP53
49	Long-term depression ³⁷	11.65	BRAF HRAS KRAS
50	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.63	EGFR HRAS KRAS

Sources

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	flotillin complex	GO:0016600	8.62	CDH1 CTNNB1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.92	BRAF CTNNB1 HRAS KRAS TP53
2	MAPK cascade	GO:0000165	9.89	BRAF EGFR HRAS KRAS
3	cell proliferation	GO:0008283	9.88	CTNNB1 EGFR HRAS PIM2 TP53
4	positive regulation of transcription, DNA-templated	GO:0045893	9.88	CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
5	Ras protein signal transduction	GO:0007265	9.75	HRAS KRAS TP53
6	cellular response to drug	GO:0035690	9.74	BRAF EGFR TP53
7	positive regulation of cell proliferation	GO:0008284	9.73	CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
8	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.71	HRAS KRAS MUC2
9	positive regulation of MAP kinase activity	GO:0043406	9.69	EGFR HRAS KRAS
10	negative regulation of neuron apoptotic process	GO:0043524	9.62	BRAF HRAS KRAS MSH2
11	positive regulation of isotype switching to IgG isotypes	GO:0048304	9.6	MLH1 MSH2
12	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.58	EGFR TP53
13	entry of bacterium into host cell	GO:0035635	9.56	CDH1 CTNNB1
14	positive regulation of fibroblast growth factor receptor signaling pathway	GO:0045743	9.55	CTNNB1 FGFBP1
15	response to isolation stress	GO:0035900	9.49	HRAS KRAS
16	cellular response to indole-3-methanol	GO:0071681	9.46	CDH1 CTNNB1
17	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.43	MLH1 MSH2
18	negative regulation of cell proliferation	GO:0008285	9.43	CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
19	somatic recombination of immunoglobulin gene segments	GO:0016447	9.37	MLH1 MSH2
20	negative regulation of apoptotic process	GO:0043066	9.17	AURKA BRAF CEACAM5 CTNNB1 EGFR PIM2
21	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.16	MLH1 MSH2

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase activity	GO:0004672	9.88	AURKA BRAF CDK8 EGFR PIM2
2	protein heterodimerization activity	GO:0046982	9.85	AURKA BRAF CTNNB1 EGFR TP53
3	protein kinase binding	GO:0019901	9.77	AURKA CTNNB1 EGFR MSH2 TP53
4	ATP binding	GO:0005524	9.76	AURKA BRAF CDK8 EGFR MLH1 MSH2
5	chromatin binding	GO:0003682	9.72	CTNNB1 EGFR MLH1 MSH2 TP53
6	protein phosphatase binding	GO:0019903	9.58	CTNNB1 EGFR TP53
7	mismatched DNA binding	GO:0030983	9.43	MLH1 MSH2
8	enzyme binding	GO:0019899	9.35	CTNNB1 EGFR MLH1 MSH2 TP53
9	guanine/thymine mispair binding	GO:0032137	9.26	MLH1 MSH2
10	nucleotide binding	GO:0000166	9.1	AURKA BRAF EGFR HRAS KRAS PIM2

Sources

Sources for Colorectal Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia